Severe Refractory Atopic Dermatitis in an Adolescent Patient Successfully Treated with Ustekinumab
- Affiliations
-
- 1Department of Dermatology, Hospital General Universitario de Valencia, Valencia, Spain.
- 2Deparment of Dermatology, Instituto Valenciano de Oncologia, Valencia, Spain. francescmb@comv.es
- KMID: 2265881
- DOI: http://doi.org/10.5021/ad.2013.25.3.368
Abstract
- No abstract available.
MeSH Terms
Figure
-
Fig. 1 Patient lesions in January 2011, erythematous scaly plaques over 80% of her total body surface (SCORing atopic dermatitis [SCORAD]: 23).
Fig. 2 Histopathologic findings of skin biopsy specimen from eczematous lesion before treatment, revealing features of subacute eczema with irregular acanthosis of epidermis, moderate spongiosis, and mixed cellular infiltrate of lymphocytes and histiocytes (H&E, ×100).
Fig. 3 Absence of lesions in July 2011 (SCORing atopic dermatitis [SCORAD]: 0), 4 months after starting ustekinumab.
Cited by 2 articles
-
Erythrodermic Psoriasis Improved by Ustekinumab: A Report of Two Cases
Ye Seul Kim, Hyun Ju Kim, Sanghoon Lee, Young Lip Park
Ann Dermatol. 2016;28(1):121-122. doi: 10.5021/ad.2016.28.1.121.Multiple Lentigines Arising in Sites of Resolving Psoriatic Plaques after Treatment with Ustekinumab
Jeong Soo Kim, Seul Ki Lee, Ha Ryeong Ryu, Chul Hyun Yun, Jin Ok Baek, Joo Young Roh, Jong Rok Lee
Ann Dermatol. 2018;30(3):371-372. doi: 10.5021/ad.2018.30.3.371.
Reference
-
1. Hu Y, Shen F, Crellin NK, Ouyang W. The IL-17 pathway as a major therapeutic target in autoimmune diseases. Ann N Y Acad Sci. 2011; 1217:60–76.
Article2. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009; 129:1339–1350.
Article3. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008; 128:2625–2630.
Article4. Hayashida S, Uchi H, Moroi Y, Furue M. Decrease in circulating Th17 cells correlates with increased levels of CCL17, IgE and eosinophils in atopic dermatitis. J Dermatol Sci. 2011; 61:180–186.
Article5. Puya R, Alvarez-López M, Velez A, Casas Asuncion E, Moreno JC. Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol. 2012; 51:115–116.
Article
